Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
3.97
Dollar change
-0.20
Percentage change
-4.80
%
Index- P/E- EPS (ttm)-1.16 Insider Own25.20% Shs Outstand186.96M Perf Week0.51%
Market Cap742.47M Forward P/E- EPS next Y-0.48 Insider Trans0.00% Shs Float139.88M Perf Month27.65%
Income-118.00M PEG- EPS next Q-0.10 Inst Own69.91% Short Float11.53% Perf Quarter72.61%
Sales14.16M P/S52.43 EPS this Y56.63% Inst Trans-1.76% Short Ratio6.57 Perf Half Y120.56%
Book/sh0.29 P/B13.79 EPS next Y-14.19% ROA-92.70% Short Interest16.12M Perf Year440.14%
Cash/sh0.67 P/C5.97 EPS next 5Y- ROE-606.69% 52W Range0.50 - 4.32 Perf YTD124.29%
Dividend Est.- P/FCF- EPS past 5Y-137.69% ROI-104.56% 52W High-8.10% Beta0.50
Dividend TTM- Quick Ratio3.36 Sales past 5Y129.39% Gross Margin87.81% 52W Low694.00% ATR (14)0.27
Dividend Ex-Date- Current Ratio3.36 EPS Y/Y TTM57.75% Oper. Margin-559.09% RSI (14)64.67 Volatility7.26% 7.31%
Employees52 Debt/Eq1.13 Sales Y/Y TTM96.39% Profit Margin-833.60% Recom1.10 Target Price6.95
Option/ShortYes / Yes LT Debt/Eq1.10 EPS Q/Q62.67% Payout- Rel Volume0.57 Prev Close4.17
Sales Surprise18.36% EPS Surprise6.80% Sales Q/Q-27.52% EarningsMay 14 AMC Avg Volume2.46M Price3.97
SMA2014.72% SMA5035.23% SMA20064.57% Trades Volume1,394,775 Change-4.80%
Date Action Analyst Rating Change Price Target Change
Apr-09-24Initiated Piper Sandler Overweight $9
Feb-01-23Downgrade Jefferies Buy → Hold $14 → $1.50
Jan-27-23Downgrade Morgan Stanley Overweight → Equal-Weight $23 → $3
Nov-09-22Downgrade Goldman Buy → Neutral $16 → $3
Mar-09-22Initiated Robert W. Baird Outperform $26
Mar-01-22Initiated Wells Fargo Overweight $25
Feb-18-22Initiated SMBC Nikko Outperform $25
Dec-16-21Initiated Guggenheim Buy $28
Jul-16-21Initiated Needham Buy $45
Jun-24-21Initiated Truist Buy $60
Jun-12-24 07:00AM
Jun-07-24 08:00AM
Jun-03-24 04:31PM
04:17PM
May-15-24 03:11AM
08:57PM Loading…
May-14-24 08:57PM
05:15PM
05:03PM
04:01PM
May-07-24 04:05PM
May-03-24 04:05PM
May-02-24 10:01AM
08:00AM
Apr-29-24 01:37PM
Apr-15-24 05:30AM
08:00AM Loading…
Apr-05-24 08:00AM
Mar-20-24 11:19AM
08:01AM
Mar-19-24 08:53PM
04:01PM
Mar-14-24 04:26PM
Mar-01-24 05:08PM
Feb-29-24 08:00AM
Feb-15-24 04:01PM
Feb-02-24 08:00AM
Jan-31-24 02:23PM
Jan-22-24 08:00AM
Jan-15-24 09:30AM
Jan-10-24 08:00AM
Jan-05-24 08:00AM
07:30AM Loading…
Dec-19-23 07:30AM
Nov-29-23 08:00AM
Nov-15-23 02:00PM
12:52PM
Nov-14-23 06:35PM
04:08PM
Nov-07-23 08:00AM
Oct-24-23 08:00AM
Oct-10-23 08:00AM
Sep-26-23 08:00AM
Sep-19-23 04:01PM
Sep-05-23 09:55AM
Sep-04-23 03:04PM
Aug-24-23 08:00AM
Aug-15-23 01:54AM
Aug-14-23 07:02AM
07:00AM
Jul-31-23 08:00AM
Jul-18-23 07:08AM
Jun-28-23 08:00AM
Jun-15-23 08:00AM
Jun-05-23 08:00AM
May-19-23 12:54PM
08:00AM
May-16-23 11:41AM
May-12-23 10:15AM
May-11-23 04:01PM
May-04-23 08:00AM
Apr-27-23 04:52PM
Apr-15-23 08:24AM
Mar-30-23 06:08AM
Mar-28-23 04:01PM
Mar-15-23 04:01PM
Feb-14-23 05:32PM
Feb-08-23 05:42AM
Jan-31-23 04:01PM
Jan-24-23 02:32PM
Dec-19-22 02:05PM
Dec-16-22 06:19PM
Dec-01-22 09:55AM
Nov-29-22 04:01PM
Nov-08-22 07:00AM
Nov-03-22 08:26PM
Nov-02-22 07:00AM
Oct-26-22 07:54PM
11:05AM
06:13AM
Oct-25-22 04:01PM
03:55PM
09:31AM
08:15AM
Oct-24-22 07:35PM
07:30PM
Oct-06-22 07:00AM
Aug-29-22 07:35AM
Aug-12-22 08:30AM
Aug-11-22 07:00AM
Aug-09-22 05:22PM
Aug-01-22 07:00AM
Jul-19-22 08:39AM
Jul-06-22 07:00AM
Jun-13-22 08:39AM
Jun-02-22 07:00AM
May-16-22 08:00PM
07:00AM
May-11-22 07:00AM
May-10-22 07:00AM
May-07-22 10:57AM
May-03-22 07:00AM
Apr-25-22 07:00AM
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Manning Paul B10% OwnerNov 17 '23Buy1.63100,000163,00016,566,667Nov 20 07:35 AM
Alam KamranChief Financial OfficerAug 24 '23Sale2.3333,00076,890258,042Aug 25 04:30 PM
Manning Paul B10% OwnerAug 16 '23Buy0.9016,466,66714,820,00016,466,667Aug 16 08:57 PM
Nolan Sean P.Chief Executive OfficerAug 16 '23Buy0.90444,444400,0001,535,545Aug 16 08:52 PM
Stalfort John A IIIDirectorAug 16 '23Buy0.90388,889350,000884,290Aug 16 08:53 PM
Stalfort John A IIIDirectorAug 16 '23Buy0.90388,889350,000999,381Aug 16 08:53 PM
Donenberg Phillip B.DirectorAug 16 '23Buy0.90111,111100,000114,111Aug 16 08:51 PM
Session R.A. II10% OwnerJul 13 '23Sale0.705,3443,7418,871,747Jul 14 04:00 PM
Session R.A. II10% OwnerJul 12 '23Sale0.7180,52857,0308,877,091Jul 14 04:00 PM
Session R.A. II10% OwnerJun 23 '23Sale0.7018,10012,7358,957,619Jun 26 04:46 PM
Session R.A. II10% OwnerJun 22 '23Sale0.7010,5087,3848,975,719Jun 26 04:46 PM
Session R.A. II10% OwnerJun 21 '23Sale0.70138,96297,6358,986,227Jun 22 04:00 PM
Session R.A. II10% OwnerJun 20 '23Sale0.71295,653210,2099,125,189Jun 22 04:00 PM
Last Close
Jun 14 04:00PM ET
8.12
Dollar change
-0.44
Percentage change
-5.14
%
IndexRUT P/E- EPS (ttm)-1.75 Insider Own39.25% Shs Outstand42.41M Perf Week-0.73%
Market Cap344.45M Forward P/E- EPS next Y-0.91 Insider Trans14.12% Shs Float25.77M Perf Month-10.77%
Income-80.74M PEG- EPS next Q-0.41 Inst Own41.92% Short Float13.73% Perf Quarter69.17%
Sales8.91M P/S38.66 EPS this Y-1.76% Inst Trans-9.35% Short Ratio17.96 Perf Half Y111.46%
Book/sh0.04 P/B227.83 EPS next Y39.90% ROA-119.65% Short Interest3.54M Perf Year28.08%
Cash/sh1.15 P/C7.04 EPS next 5Y- ROE-243.34% 52W Range2.86 - 11.41 Perf YTD10.93%
Dividend Est.- P/FCF- EPS past 5Y-0.97% ROI-171.98% 52W High-28.83% Beta1.59
Dividend TTM- Quick Ratio3.04 Sales past 5Y-13.60% Gross Margin76.09% 52W Low183.92% ATR (14)0.66
Dividend Ex-Date- Current Ratio3.17 EPS Y/Y TTM-162.67% Oper. Margin-838.45% RSI (14)47.31 Volatility9.01% 7.67%
Employees100 Debt/Eq30.75 Sales Y/Y TTM3.18% Profit Margin-905.83% Recom1.00 Target Price15.50
Option/ShortYes / Yes LT Debt/Eq30.09 EPS Q/Q-185.51% Payout- Rel Volume0.55 Prev Close8.56
Sales Surprise36.29% EPS Surprise1.57% Sales Q/Q10240.54% EarningsMay 13 BMO Avg Volume196.95K Price8.12
SMA20-5.89% SMA503.77% SMA20047.67% Trades Volume108,791 Change-5.14%
Date Action Analyst Rating Change Price Target Change
Jul-25-23Upgrade Needham Hold → Buy $10
Mar-22-23Initiated Jefferies Buy $10
Feb-13-23Upgrade RBC Capital Mkts Sector Perform → Outperform $4 → $11
May-25-22Downgrade RBC Capital Mkts Outperform → Sector Perform $16 → $4
May-14-21Initiated RBC Capital Mkts Outperform $19
Dec-24-20Reiterated H.C. Wainwright Buy $18 → $21
Jul-15-20Downgrade BofA Securities Buy → Neutral
Jun-30-20Reiterated H.C. Wainwright Buy $24 → $18
Jun-24-20Initiated Northland Capital Outperform $21
Mar-24-20Initiated Needham Buy $20
May-30-24 04:30PM
May-15-24 09:11AM
07:30AM
May-14-24 09:28AM
08:50AM
03:01AM Loading…
03:01AM
May-13-24 11:53AM
09:12AM
08:40AM
07:30AM
May-09-24 07:30AM
May-08-24 07:30AM
May-06-24 06:35AM
Apr-27-24 06:00AM
Apr-02-24 07:30AM
07:30AM Loading…
Mar-26-24 07:30AM
Mar-01-24 09:10AM
Feb-29-24 08:11AM
07:30AM
Feb-27-24 07:30AM
Feb-22-24 07:30AM
Feb-05-24 07:30AM
Jan-29-24 07:30AM
Jan-22-24 07:44PM
Jan-05-24 07:30AM
Jan-04-24 07:30AM
Jan-03-24 07:30AM
Dec-15-23 01:49PM
06:00AM
Nov-11-23 10:13AM
08:00AM Loading…
Nov-10-23 08:00AM
Nov-09-23 07:30AM
Oct-25-23 07:00AM
Sep-27-23 08:00AM
Aug-31-23 08:00AM
Aug-24-23 08:30AM
Aug-23-23 07:30AM
Aug-10-23 04:05PM
Aug-08-23 07:30AM
Aug-03-23 07:30AM
Jul-27-23 06:06AM
Jul-26-23 04:05PM
Jul-25-23 07:16AM
Jul-24-23 03:16PM
07:00AM
Jul-21-23 04:47PM
04:30PM
04:24PM
Jul-17-23 07:22AM
Jul-12-23 03:16AM
May-31-23 07:00AM
May-30-23 12:34PM
May-10-23 07:30AM
06:11AM
May-09-23 07:30AM
May-05-23 09:07AM
Apr-26-23 08:01PM
Apr-12-23 07:00AM
Apr-11-23 07:00AM
Mar-06-23 07:30AM
Feb-28-23 04:05PM
Feb-27-23 04:05PM
Feb-22-23 11:49AM
Feb-21-23 07:22AM
Feb-17-23 06:43PM
Feb-14-23 10:15AM
Jan-24-23 07:30AM
07:16AM
Jan-04-23 07:30AM
Jan-01-23 08:16AM
Dec-12-22 12:07PM
Nov-26-22 07:00AM
Nov-07-22 04:05PM
Aug-31-22 04:30PM
Aug-17-22 07:53AM
Aug-11-22 07:30AM
Aug-04-22 01:38PM
12:34PM
Aug-03-22 12:02PM
Aug-01-22 07:30AM
Jul-20-22 12:00PM
Jul-18-22 11:43AM
Jul-07-22 06:10AM
Jul-06-22 09:31AM
Jul-01-22 09:36AM
Jun-29-22 09:23PM
04:01PM
03:26PM
Jun-28-22 07:30AM
Jun-17-22 09:35AM
Jun-13-22 09:55AM
Jun-05-22 08:42AM
Jun-01-22 09:35AM
May-26-22 03:37PM
May-25-22 03:14PM
08:18AM
06:39AM
May-24-22 09:12PM
08:00PM
May-17-22 11:53AM
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerDec 29 '23Buy7.24115,774838,2047,099,182Dec 29 05:27 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 28 '23Buy7.08126,116892,9016,983,408Dec 29 05:27 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 27 '23Buy7.2079,726574,0276,857,292Dec 29 05:27 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 26 '23Buy6.4954,652354,6916,777,566Dec 26 07:21 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 22 '23Buy6.67250,0001,667,5006,722,914Dec 26 07:21 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 21 '23Buy6.17200,0001,234,0006,472,914Dec 26 07:21 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 19 '23Buy5.36277,0081,484,7636,272,914Dec 19 05:52 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 18 '23Buy5.41456,9232,471,9535,995,906Dec 19 05:52 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 15 '23Buy5.97500,0002,985,0005,538,983Dec 19 05:52 PM
Hayes Christopher G.Chief Legal OfficerNov 15 '23Sale2.9711,55834,327123,226Nov 16 04:32 PM
White TedPresident and CEONov 15 '23Sale2.9711,55834,327170,090Nov 16 04:33 PM
Bonaccorso JoeChief Commercial OfficerNov 15 '23Sale2.9711,26633,46092,392Nov 16 04:49 PM
Kohler TerryChief Financial OfficerNov 15 '23Sale2.979,63228,60734,416Nov 16 04:34 PM
Goldenberg GaryChief Medical OfficerNov 15 '23Sale2.973,0369,01786,257Nov 16 04:35 PM
Hayes Christopher G.Chief Legal OfficerNov 14 '23Sale2.9322,14164,873134,784Nov 16 04:32 PM
White TedPresident and CEONov 14 '23Sale2.9322,14164,873181,648Nov 16 04:33 PM
Bonaccorso JoeChief Commercial OfficerNov 14 '23Sale2.9321,58063,229103,658Nov 16 04:49 PM
Kohler TerryChief Financial OfficerNov 14 '23Sale2.9318,45254,06444,048Nov 16 04:34 PM
Goldenberg GaryChief Medical OfficerNov 14 '23Sale2.935,81717,04489,293Nov 16 04:35 PM
Manning Paul BDirectorJul 24 '23Buy5.02200,0001,004,0007,851,128Jul 24 06:47 PM
White TedPresident and CEOJul 24 '23Sale4.8350,677244,770128,789Jul 25 04:18 PM
Bonaccorso JoeChief Commercial OfficerJul 24 '23Sale4.8338,262184,80562,738Jul 25 04:22 PM
Hayes Christopher G.Chief Legal OfficerJul 24 '23Sale4.8333,789163,20181,925Jul 25 04:25 PM
Goldenberg GaryChief Medical OfficerJul 24 '23Sale4.8328,699138,61670,110Jul 25 04:23 PM